[go: up one dir, main page]

MA30337B1 - Anticorps - Google Patents

Anticorps

Info

Publication number
MA30337B1
MA30337B1 MA31293A MA31293A MA30337B1 MA 30337 B1 MA30337 B1 MA 30337B1 MA 31293 A MA31293 A MA 31293A MA 31293 A MA31293 A MA 31293A MA 30337 B1 MA30337 B1 MA 30337B1
Authority
MA
Morocco
Prior art keywords
antibodies
amyloid
beta
methods
antibody
Prior art date
Application number
MA31293A
Other languages
English (en)
Inventor
Stephen Anthony Burbidge
Jonathan Henry Ellis
Susannah K Ford
Volker Germaschewski
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30337B1 publication Critical patent/MA30337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des anticorps se liant au peptide (beta)-amyloïde, des méthodes destinées à traiter, au moyen de ces anticorps, des maladies ou des troubles caractérisés par des taux élevés de (beta)-amyloïde ou des dépôts de (beta)-amyloïde, des compositions pharmaceutiques comprenant lesdits anticorps ainsi que leurs procédés de fabrication.
MA31293A 2006-03-30 2008-10-15 Anticorps MA30337B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30

Publications (1)

Publication Number Publication Date
MA30337B1 true MA30337B1 (fr) 2009-04-01

Family

ID=38284050

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31293A MA30337B1 (fr) 2006-03-30 2008-10-15 Anticorps

Country Status (32)

Country Link
US (3) US8227576B2 (fr)
EP (2) EP2177536B1 (fr)
JP (1) JP5103466B2 (fr)
KR (2) KR101263294B1 (fr)
CN (2) CN103539857A (fr)
AR (1) AR060332A1 (fr)
AT (1) ATE451392T1 (fr)
AU (1) AU2007233831B2 (fr)
BR (1) BRPI0709246A2 (fr)
CA (1) CA2647808C (fr)
CR (1) CR10347A (fr)
CY (1) CY1109877T1 (fr)
DE (1) DE602007003703D1 (fr)
DK (2) DK1996621T3 (fr)
EA (1) EA015654B9 (fr)
ES (2) ES2338179T3 (fr)
HR (2) HRP20100115T1 (fr)
IL (1) IL193695A (fr)
JO (1) JO2576B1 (fr)
MA (1) MA30337B1 (fr)
MX (1) MX2008012483A (fr)
MY (1) MY149630A (fr)
NO (1) NO20083793L (fr)
NZ (1) NZ571038A (fr)
PE (1) PE20080181A1 (fr)
PL (2) PL2177536T3 (fr)
PT (2) PT2177536E (fr)
SI (2) SI1996621T1 (fr)
TW (1) TWI385179B (fr)
UA (1) UA94734C2 (fr)
WO (1) WO2007113172A2 (fr)
ZA (1) ZA200807911B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
CA2628703C (fr) 2005-11-30 2019-10-29 Abbott Laboratories Anticorps anti-globulomere a.beta., fractions de liaison aux antigenes de ceux-ci, hydridomes , acides nucleiques, vecteurs, cellules hotes correspondants, procedes de production des anticorps, compositions comprenant les anticorps, utilisations des anticorps et procedes d'utilisation de ces anticorps
EP1976877B2 (fr) 2005-11-30 2016-10-05 AbbVie Inc. Anticorps monoclonaux contre la protein beta-amyloide et utilisation de ceux-ci
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PT2182983E (pt) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
ES2473623T3 (es) * 2007-08-20 2014-07-07 Glaxo Group Limited Procedimiento de producción
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
EP2205631B1 (fr) * 2007-10-05 2016-11-23 Genentech, Inc. Anticorps humanisé
SG10201505369QA (en) 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
KR101280704B1 (ko) * 2007-10-12 2013-07-01 에프. 호프만-라 로슈 아게 다수의 핵산으로부터의 단백질 발현
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2222700A2 (fr) * 2007-11-27 2010-09-01 Medtronic, Inc. Anticorps anti-amyloïde bêta humanisés
ES2525704T3 (es) * 2007-12-11 2014-12-29 Glaxo Group Limited Proteínas de unión a antígenos
CA2709354C (fr) 2007-12-21 2014-06-17 Amgen Inc. Anticorps anti-amyloide et utilisations de ceux-ci
AR071634A1 (es) 2008-05-06 2010-06-30 Glaxo Group Ltd Nanoparticulas para encapsulacion de agentes biologicamente activos
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010063122A1 (fr) 2008-12-05 2010-06-10 Angiochem Inc. Conjugués de neurotensine ou d'analogues de neurotensine et leurs applications
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (fr) 2009-07-02 2015-05-01 Angiochem Inc
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
EP2308897A1 (fr) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Anticorps chimères spécifiques de CD151 et leurs utilisations pour le traitement du cancer
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011149461A1 (fr) * 2010-05-27 2011-12-01 Medtronic, Inc. Anticorps anti-amyloïde bêta conjugués à des molécules contenant de l'acide sialique
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
SI2646470T1 (sl) * 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
ES2714692T3 (es) 2011-01-31 2019-05-29 Tau Bio Logic Corp Tratamiento de tauopatías
CA2833019A1 (fr) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Proteines de liaison a un antigene membranaire specifique de la prostate et compositions et procedes associes
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
WO2013177062A2 (fr) 2012-05-21 2013-11-28 Genentech, Inc. Procédés pour améliorer la sécurité du transport à travers la barrière hémato-encéphalique
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
JP2016529482A (ja) 2013-06-19 2016-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 新規アッセイ
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017072090A1 (fr) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Polythérapie
US11530257B2 (en) * 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
JP7436449B2 (ja) 2018-07-17 2024-02-21 ジエンス ヘンルイ メデイシンカンパニー リミテッド 抗ａベータ抗体、その抗原結合フラグメントおよびそれらの用途
CA3135170A1 (fr) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anticorps anti-tauc3 et leurs utilisations
US12435129B2 (en) 2020-07-23 2025-10-07 Othair Prothena Limited Anti-Aβ antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) * 2024-08-19 2024-11-22 成都迈科康生物科技有限公司 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
PT994728E (pt) * 1997-04-09 2008-11-11 Intellect Neurosciences Inc Anticorpos recombinantes específicos contra terminações beta-amilóide, codificação por adn e métodos de utilização destes
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
AU2002239766B9 (en) * 2000-11-03 2007-04-05 The J. David Gladstone Institutes Methods of treating disorders related to apoE
WO2004029629A1 (fr) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法

Also Published As

Publication number Publication date
TWI385179B (zh) 2013-02-11
EP2177536A1 (fr) 2010-04-21
JP2009531380A (ja) 2009-09-03
PE20080181A1 (es) 2008-03-16
PT2177536E (pt) 2014-08-22
ATE451392T1 (de) 2009-12-15
WO2007113172A2 (fr) 2007-10-11
PL2177536T3 (pl) 2014-11-28
EA015654B1 (ru) 2011-10-31
BRPI0709246A2 (pt) 2011-07-12
MY149630A (en) 2013-09-13
EP2177536B1 (fr) 2014-06-04
US20110142824A1 (en) 2011-06-16
JP5103466B2 (ja) 2012-12-19
UA94734C2 (ru) 2011-06-10
CR10347A (es) 2008-10-29
HRP20100115T1 (hr) 2010-04-30
ES2338179T3 (es) 2010-05-04
US8227576B2 (en) 2012-07-24
HK1122311A1 (en) 2009-05-15
IL193695A0 (en) 2011-08-01
WO2007113172A3 (fr) 2007-11-29
EP1996621A2 (fr) 2008-12-03
CN101415729B (zh) 2013-09-04
AU2007233831A1 (en) 2007-10-11
SI2177536T1 (sl) 2014-09-30
DK2177536T3 (da) 2014-07-14
KR101263294B1 (ko) 2013-06-04
JO2576B1 (en) 2011-02-27
CA2647808C (fr) 2015-11-17
CN103539857A (zh) 2014-01-29
HK1138015A1 (en) 2010-08-13
US9193784B2 (en) 2015-11-24
MX2008012483A (es) 2008-10-10
CA2647808A1 (fr) 2007-10-11
KR20120093400A (ko) 2012-08-22
AR060332A1 (es) 2008-06-11
HRP20140618T1 (hr) 2014-08-15
PT1996621E (pt) 2010-03-08
ZA200807911B (en) 2009-11-25
ES2484967T3 (es) 2014-08-12
NO20083793L (no) 2008-10-13
EA015654B9 (ru) 2012-01-30
SI1996621T1 (sl) 2010-04-30
CY1109877T1 (el) 2014-09-10
PL1996621T3 (pl) 2010-05-31
DK1996621T3 (da) 2010-04-19
DE602007003703D1 (de) 2010-01-21
TW200815466A (en) 2008-04-01
AU2007233831B2 (en) 2013-02-14
NZ571038A (en) 2011-03-31
CN101415729A (zh) 2009-04-22
IL193695A (en) 2012-05-31
US20160024197A1 (en) 2016-01-28
US20140050719A1 (en) 2014-02-20
EP1996621B1 (fr) 2009-12-09
KR20080113273A (ko) 2008-12-29
EA200801842A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
MA30337B1 (fr) Anticorps
MA31999B1 (fr) Proteines de liaison a l'antigene
TNSN07398A1 (fr) Anticorps contre la p-cadherine
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
BRPI0619357A8 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
TW200642694A (en) Anti-M-CSF antibody compositions
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
WO2006122257A3 (fr) Nebulisation d'anticorps monoclonaux pour le traitement de maladies pulmonaires
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA29427B1 (fr) Antagonistes et leurs methodes d'utilisation
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer